{"title":"[Desire to have children after vasectomy : Vasectomy reversal or assisted reproductive technology?]","authors":"Armin Soave, Sabine Kliesch, Jann-Frederik Cremers","doi":"10.1007/s00120-024-02454-9","DOIUrl":"10.1007/s00120-024-02454-9","url":null,"abstract":"<p><p>The vasectomy is a safe and effective method of contraception for men. Up to 6% of men who underwent vasectomy have a renewed child wish. Microsurgical vasectomy reversal (VR) in men, microsurgical epididymal sperm aspiration (MESA), or testicular sperm extraction (TESE) in men plus assisted reproductive technology (ART) in the female partner as well as the combination of VR and MESA/TESE plus ART represent established therapeutic strategies. Various factors may impact the success of VR, as defined by patency and pregnancy rate following VR, including the female partner's age, the obstructive interval, and the surgical VR technique. There is no difference in the pregnancy and live birth rate following VR or MESA/TESE plus ART. However, following MESA/TESE plus ART, time to pregnancy is shorter compared with VR. Overall, VR is more cost-effective than MESA/TESE plus ART and allows for a lower therapeutic burden, especially in the female partner. In addition, VR combined with TESE plus-if necessary-ART is more cost-effective than MESA/TESE plus ART alone, even in female partners with advanced age. For successful counseling regarding the different therapy options for a renewed child wish after vasectomy, it is important to evaluate the underlying individual situation of the couple.</p>","PeriodicalId":29782,"journal":{"name":"Urologie","volume":" ","pages":"1111-1121"},"PeriodicalIF":0.5,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142476381","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
UrologiePub Date : 2024-11-01Epub Date: 2024-08-29DOI: 10.1007/s00120-024-02413-4
C Aydogdu, I Brinkmann, J Casuscelli
{"title":"[Novel systemic treatment options for advanced bladder cancer].","authors":"C Aydogdu, I Brinkmann, J Casuscelli","doi":"10.1007/s00120-024-02413-4","DOIUrl":"10.1007/s00120-024-02413-4","url":null,"abstract":"<p><p>Systemic treatment of urothelial carcinoma of the bladder requires complex approaches and is constantly evolving. Neoadjuvant cisplatin-based chemotherapy followed by radical cystectomy remains the current standard of care for muscle-invasive advanced bladder cancer. For patients ineligible for cisplatin, adjuvant treatment with nivolumab is recommended. Innovative perioperative combinations could transform the treatment landscape in the future. First-line treatment for metastatic urothelial carcinoma has long been dominated by platinum-based combinations, recently followed by the immune checkpoint inhibitor avelumab as maintenance therapy; however, recent results on the use of enfortumab vedotin and pembrolizumab in the first-line setting are expected to fundamentally change the treatment options. In subsequent lines of treatment, the not yet approved erdafitinib, as the first targeted therapy for advanced urothelial carcinoma, offers an important alternative and underscores the need for molecular testing.</p>","PeriodicalId":29782,"journal":{"name":"Urologie","volume":" ","pages":"1162-1173"},"PeriodicalIF":0.5,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142112792","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
UrologiePub Date : 2024-11-01Epub Date: 2024-08-27DOI: 10.1007/s00120-024-02392-6
Friedrich H Moll, Heiner Fangerau
{"title":"[Early sources of urologic and venereologic sexual medicine from Vienna : Protagonists at the interface of two new medical specialties].","authors":"Friedrich H Moll, Heiner Fangerau","doi":"10.1007/s00120-024-02392-6","DOIUrl":"10.1007/s00120-024-02392-6","url":null,"abstract":"<p><p>The Austrian Society for the Promotion of Sexual Medicine and Sexual Health (Österreichische Gesellschaft zur Förderung der Sexualmedizin und der Sexuellen Gesundheit [ÖGFSSG]) was founded in 2014. This foundation looked back upon the increasing efforts to develop this field of academic knowledge since the middle of the 19th century, in which Viennese medicine played an important role. This article highlights key Viennese players who had a particular interest in sexual medicine from a urological perspective around 1900. They worked in the wider area of several disciplines, striving for specialization in the environment of a rapidly growing metropolis with multiple cultural influences. The scholars presented here as a collection of sources contributed to the upswing in sexual medicine through their work by venturing into an area in which no medical or other discipline had previously been able to claim sovereignty of interpretation.</p>","PeriodicalId":29782,"journal":{"name":"Urologie","volume":" ","pages":"1137-1150"},"PeriodicalIF":0.5,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11549156/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142074111","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
UrologiePub Date : 2024-11-01DOI: 10.1007/s00120-024-02468-3
{"title":"BvDU Kurz notiert.","authors":"","doi":"10.1007/s00120-024-02468-3","DOIUrl":"10.1007/s00120-024-02468-3","url":null,"abstract":"","PeriodicalId":29782,"journal":{"name":"Urologie","volume":"63 11","pages":"1191-1192"},"PeriodicalIF":0.5,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142606509","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}